一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括JNJ-79635322；Teclistamab，当前状态为招募中。登记地点显示中国北京、成都、广州、杭州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
JNJ-79635322；Teclistamab · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital · 北京
- Peking University People's Hospital · 北京
- Sichuan Provincial Peoples Hospital · 成都
- Sun Yat Sen University Cancer Center · 广州
- First affiliated Hospital of Zhejiang University · 杭州
- Nanjing Drum Tower Hospital · 南京
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- Shanghai Fourth People s Hospital · 上海
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Wuhan Tongji Hospital Tongji Medical College · 武汉
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
公开的入选条件
- Inclusion:
- * Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:
- 1. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
- 2. Measurable disease at screening as assessed by central laboratory
- * Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody
- * Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria
- * Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better
- * Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07258511；登记信息更新于 2026-09-25。